The clinical and microbiological characteristics of infections caused by Scedosporium/ Lomentospora species in 21 patients are described. We searched retrospectively the records for Scedosporium/ Lomentospora species seen at the University Hospital Virgen de las Nieves from 2006 to 2017. Out of them, 16 were male; mean age at diagnosis was 57.8 (±SD 15) years; all patients had risk factors for fungal infection such as corticosteroids and/or immunosuppressive treatment in 18 (85.7%) patients, pulmonary diseases in seven (33.3%) cases, hematological malignancies in six (28.5%), and organ transplantation in three (14.2%) patients. Most patients had infection in the lung/pleura (17/80.9%); cough was present in 12 patients and dyspnea in another 12, and the mean interval until diagnosis was 13.6 days. The most frequent species was S. apiospermum/S. boydii in 14 patients (66.6%), followed by L. prolificans in seven. The diagnosis was obtained from sputum in 12 (57.1%) cases, followed by pleural fluid and bronchoalveolar lavage in two of each. The most frequently used antifungals were voriconazole and amphotericin B, but combination of more than one antifungal drug was only used in three patients. Ten patients were cured, and six patients died as a consequence of the infection; three patients had chronic infection. In general, infections caused by Scedosporium/ Lomentospora species are rare, serious, and difficult to diagnose and treat, having a high index or mortality especially in those caused by L. prolificans.
Introduction
Scedosporium spp. are fungal opportunistic pathogens causing serious infections difficult to treat. S. prolificans and S. apiospermum are the only recognized species that recently belonged to this genus, although molecular studies have demonstrated that S. apiospermum is a complex composed by five species. 1, 2 Moreover, S. prolificans is genetically distinct from the other Scedosporium species, and it was reassigned to the genus Lomentospora and is now called L. prolificans. 2 Both species may cause invasive fungal disease with similar pathogeny, clinical manifestations, and severity, although they may act as surface or body cavities colonizers such as in patients with cystic fibrosis. 3 In the last years, the infections caused by Scedosporium/Lomentospora species have increased, especially in immunossupressed patients, and are characterized by both their virulence and resistance to the majority of antifungals. Recently, we were confronted with a fatal case of pleural infection due to S. apiospermium (case 10). Due to its rarity, we have retrospectively reviewed the records of all cases seen in our hospital in the last 11 years, and we have analysed the most important clinical and microbiologic findings.
Methods
We describe the clinical and microbiologic characteristics of 21 patients with Scedosporium/Lomentospora infection seen at the University Hospital Virgen de las Nieves (Granada, Spain) during the period 2006-2017.
We traced 41 cases caused by Scedosporium/ Lomentospora described in sufficient detail through their clinical histories. We defined Scedosporium/Lomentospora infection according previous published guidelines. 4, 5 Of the 41 patients with positive cultures for Scedosporium/Lomentospora, only 21 met the criteria for "proven" or "probable" infection. 4 Data on age and sex, localization of infection, fungal species, risk factors and/or underlying diseases, time until diagnosis, clinical manifestations, laboratory and radiological findings, microbiologic diagnosis, treatment, and outcome were recorded. Inoculation of media was performed according the type of sample following the standardized procedures in our laboratory. Overall, the specimens were inoculated in aer- Definitive diagnosis was performed by specimen culture and macroscopic appearance (Fig. 1) , observation of fungal elements by microscopy ( Fig. 2) 6 and, in some instances (cases 10 and 13), by molecular methods such as polymerase chain reaction (PCR), performing sequentiation of both the ITS and the β-tubulin with the TUB-F and TUB-R primers 7 and proteomic techniques such as Maldi-tof (Bruker Biotyper, Billerica, MA, USA). 8 In two cases (10 and 13), the strain was sent to the National Centre of Microbiology (Majadahonda, Madrid, Spain) for susceptibility study, which was performed according to the EUCAST method. 
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Results
General characteristics
Clinical manifestations
Clinical findings depended on location of infection. Pulmonary or pleural location was found in the majority of patients (17/80.9%), followed by periorbital, mediastinal, blood and skin location in one patient each. Nineteen (90.4%) patients had more than one sign or symptom of disease. As the main location was the lung, cough and dyspnea were reported in 12 (57.1%) patients each. The second most frequent symptom was fever in six (28.5%) patients, and chest pain was found in five (23.8%) cases.
Microbiology, laboratory and radiological findings
At the diagnosis of fungal infection, data on the CRP level were reported in 11 (52.3%) patients. The mean CRP level was 44.8 mg/L (range 0.9-387.7). On the other hand, neutropenia (neutrophils <1500/μl) was only found in 2 (15.3%) from 13 patients in whom laboratory data were reported. The most frequently isolated Scedosporium/ Lomentospora species was S. apiospermum/S. boydii, found in 14 (66.6%) patients, and L. prolificans in 7 (33.3%). These species were diagnosed by culture of sputum in 12 (57.1%) cases, culture of pleural or bronchoalveolar lavage fluid in 2 (9.5%) cases each one, and culture of periorbital and medistinal abscess, skin biopsy and blood in 1 (4.7%) each one. Susceptibility tests for S. apiospermun/S. boydii were only performed in 2 isolates (cases 10 and 13). In the case 10, the MIC obtained were as follows (mcg/mL): amphotericin B 4, itraconazole >8, voriconazole 8, posaconazole >8, terbinafine >16, caspofungin 16, micafungin 0.25, and anidulafungin >4. On the other hand, in the case 13 the MICs were as follows (mcg/mL): amphotericin B 1, itraconazole >8, voriconazole 1, posaconazole 2, terbinafine >16, caspofugin 2, micafungin 0.25, and anidulafungin 8.
Regarding radiological alterations, condensation signs were observed in eight (44.4%) patients, followed by both pleural effusion and bronchiectasias in five (27.7%) of each; nodules were seen in four (22.2%) patients. Eleven (61.1%) patients had more than one radiological finding.
Antifungal treatment
Twenty (95.2%) patients underwent antifungal treatment, with a single drug in 17 (80.9%) cases, with two drugs in two (10%) cases, and more than two in one case (5%). The majority of them were treated with voriconazole (17/80.9%) and three (14.2%) with amphotericin B. One patient (case 3) was treated with both voriconazole and surgery (debridement and abscess drainage).
Outcome
The final outcome was not obtained in two patients. A favorable outcome was recorded in nine (45%) patients after antifungal treatment and in one patient after antifungal plus surgical treatment. Six patients (30%) died, and three patients (20%) had recurrent infection attributable to the original fungal microorganism after antifungal treatment.
Discussion
Infections caused by Scedosporium/Lomentospora species are still a rare event, although the incidence is increasing due to the largest number of immunossupressed patients or with other underlying diseases for this infection. 10 Recently, several case reports of Scedosporium/ Lomentospora infection have been published in the medical literature. [11] [12] [13] [14] [15] Endocarditis and osteomyelitis in transplanted patients have been described 11, 12 but also epidural abscess, disseminated infection, and tenosynovitis caused in immunocompetent patients. [13] [14] [15] We were able to trace 21 cases of Scedosporium/ Lomentospora infection from our institution reported in sufficient detail for comparison, showing that S. apiospermum/S. boydii is the main species responsible in our health area.
Risk factors for fungal infection, including IS therapy and/or corticosteroids use, pulmonary or haematologic diseases, presence of neutropenia or GVHD play a decisive role in the development of invasive fungal infections. The majority of Scedosporium/Lomentospora infections are associated with IS and/or corticosteroids treatment (85.7%), and the presence of haematologic malignancies and pulmonary diseases, so the absence of any of these factors may make the diagnosis doubtful or unlikely. These data are similar to a previous published series of patients with Scedosporium/Lomentospora infection in whom 80% of them received corticosteroids after diagnosis. 16 However, Idígoras et al. 17 found only 22% of patients receiving IS and/or corticosteroids treatment. Classically, neutropenia has been considered as a risk factor for IFI. However, only two of our patients demonstrate to have a low neutrophils count. Other studies have reported neutropenia percentages ranging 44 to 52%. 16, 17 A possible explanation of these differences may be due to the fact that in eight of our patients there were not laboratory records for this item.
According to our results, lung and/or pleura is the most frequent location in these kinds of patients, as previously has been reported 17 ; thus, the symptomatology referred to this area such as cough, dyspnea, and chest pain is the most common, and the presence of other symptoms depend on the location of infection. Disseminated infection, however, was the most common presentation in another study. 16 although 88% of patients with disseminated infection had concomitant pneumonia. The onset of symptoms is generally acute and development of the disease can be rapid. Based on data for 13 patients, the mean time between onset of symptoms and diagnosis was 13.6 days; therefore, this infection should be suspected in cases with acute symptoms. One of the main issues to elucidate is whether the presence of Scedosporium/Lomentospora species in samples can be considered as a contaminant or not, because there is still no standard diagnostic criteria for invasive fungal infections (IFI). Respiratory tract is the most frequent colonization site in these pathogens, although the colonization rate in health people is unknown. 18 Moreover, Scedosporium/ Lomentospora species are frequent colonizers of the respiratory tract in cystic fibrosis patients. 3 In 2002, an international consensus defining opportunistic IFI in immunocompromised patients was published. 4 Three levels of probability were proposed but only patients with "proven" or in which several recommendations for the diagnosis were given. However, further studies are urgently needed in order to definitively establish criteria for opportunistic IFI. In this review, the majority of patients were diagnosed by culture of sputum specimens; however, the bronchoalveolar lavage fluid is the sample of choice for the diagnosis of the infection located at the low respiratory tract (cases 1 and 2). Sputum or tracheal aspirate samples only have a presumptive value in infections caused by opportunistic fungi, because there are not any criteria for differentiation between infection, colonization and contamination. In these cases, its value is very conditioned by the sample quality. 19 When the sample is not the most appropriate for diagnosis, the inclusion in the "proven" or "probable" levels of infection should be established by the presence of additional factors such as the existence of clinical symptomatology and radiological findings consistent with infection. 4 The antifungal treatment of choice for Scedosporium/ Lomentospora infection has not yet been established due to its rarity, and management of these infections depends on the underlying condition of the host. The use of antifungal agents is still a challenging issue, because of the high resistance of these fungi to most antifungal and the severity of the underlying diseases in the host. S. apiospermum/S. boydii is resistant to amphotericin B and flucytosine, and demonstrated variable susceptibility to itraconazole, voriconazole, posaconazole, and micafungin. 20 16 On the other hand, any of the treatments administered in the series from Idigoras et al. showed advantages, alone or in combination. 17 In line with this latest work, any of the treatments administered to our patients showed higher survival rate. This seems clear that in localized cases in immunocompetent patients (case 3), treatment with an antifungal drug plus surgical debridement may lead to eradicate the infection. Some factors such as the immunossupression level, underlying diseases, and location of infection may be determinant for patient survival. In our patients, the mortality rate in L. prolificans infection is higher than in S. apiospermium/S. boydii (42.8 vs.
21.4%).
The heterogeneity of studies and scarcity of data prevents any conclusion being drawn on antifungal treatments, and further research is required on this important issue. It appears evident that these patients should be treated with drugs selected after antifungal susceptibility tests, but the absence of standardization of the methods and that these techniques are usually performed in reference centres, make it very difficult to carry out.
In conclusion, infections caused by Scedosporium/ Lomentospora species are still rare and difficult to diagnose and treat. These infections should be suspected especially in patients with corticosteroids and/or IS treatment as well as in those with hematologic malignancies or pulmonary diseases. Due to the absence of diagnostic criteria clearly established for IFI and that these opportunistic pathogens are frequent colonizers, the diagnosis should be confirmed microbiologically, taking adequate samples from the affected tissue, and leaning on clinical and radiological diagnosis criteria. Despite the above mentioned difficulties, antifungal susceptibility testing of isolates is also highly recommended in order to detect the presence of resistances. The treatment is still a challenge issue, and it is not clearly defined, being the mortality rate high in this kind of infections, especially in those caused by L. prolificans.
